Epigenetic biomarker development - PubMed (original) (raw)

Review

Epigenetic biomarker development

Christoph Bock. Epigenomics. 2009 Oct.

Abstract

Epigenetic mechanisms control gene expression in a way that is stably propagated over multiple cell divisions, but which is also flexible enough to respond to environmental influences. This intermediate position between stability and plasticity renders epigenetic information highly useful for monitoring cellular states in the context of personalized medicine. Epigenetic alterations have also been identified as causal events for common diseases such as cancer and autoimmune disorders. The goal of epigenetic biomarker development is to design experimental assays that produce relevant information for diagnosis, prognosis and therapy optimization in routine clinical treatment and drug discovery. Here, I outline a systematic approach to epigenetic biomarker development and highlight key bioinformatic tools that facilitate discovery, optimization and validation of novel biomarkers.

PubMed Disclaimer

Similar articles

• Use of DNA methylation for cancer detection: promises and challenges.
  Zhu J, Yao X. Zhu J, et al. Int J Biochem Cell Biol. 2009 Jan;41(1):147-54. doi: 10.1016/j.biocel.2008.09.003. Epub 2008 Sep 13. Int J Biochem Cell Biol. 2009. PMID: 18834953 Review.
• Computational epigenetics.
  Bock C, Lengauer T. Bock C, et al. Bioinformatics. 2008 Jan 1;24(1):1-10. doi: 10.1093/bioinformatics/btm546. Epub 2007 Nov 17. Bioinformatics. 2008. PMID: 18024971 Review.
• Epigenetic profiling joins personalized cancer medicine.
  Heyn H, Méndez-González J, Esteller M. Heyn H, et al. Expert Rev Mol Diagn. 2013 Jun;13(5):473-9. doi: 10.1586/erm.13.36. Expert Rev Mol Diagn. 2013. PMID: 23782254 Review.
• DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker.
  Tost J. Tost J. Methods Mol Biol. 2009;507:3-20. doi: 10.1007/978-1-59745-522-0_1. Methods Mol Biol. 2009. PMID: 18987802 Review.
• Epigenetic biomarkers in cancer epidemiology.
  Verma M. Verma M. Methods Mol Biol. 2012;863:467-80. doi: 10.1007/978-1-61779-612-8_28. Methods Mol Biol. 2012. PMID: 22359311 Review.

Cited by

• Global scientific trends in research of epigenetic response to exercise: A bibliometric analysis.
  Wu H, Hu Y, Jiang C, Chen C. Wu H, et al. Heliyon. 2024 Feb 6;10(4):e25644. doi: 10.1016/j.heliyon.2024.e25644. eCollection 2024 Feb 29. Heliyon. 2024. PMID: 38370173 Free PMC article. Review.
• The role of microRNAs in pathophysiology and diagnostics of metabolic complications in obstructive sleep apnea patients.
  Karuga FF, Jaromirska J, Malicki M, Sochal M, Szmyd B, Białasiewicz P, Strzelecki D, Gabryelska A. Karuga FF, et al. Front Mol Neurosci. 2023 Jul 21;16:1208886. doi: 10.3389/fnmol.2023.1208886. eCollection 2023. Front Mol Neurosci. 2023. PMID: 37547923 Free PMC article. Review.
• Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?
  Teixeira-Marques A, Lourenço C, Oliveira MC, Henrique R, Jerónimo C. Teixeira-Marques A, et al. Int J Mol Sci. 2023 Apr 4;24(7):6757. doi: 10.3390/ijms24076757. Int J Mol Sci. 2023. PMID: 37047731 Free PMC article. Review.
• Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases.
  de la Calle-Fabregat C, Rodríguez-Ubreva J, Cañete JD, Ballestar E. de la Calle-Fabregat C, et al. Rheumatol Immunol Res. 2022 Oct 20;3(3):103-110. doi: 10.2478/rir-2022-0018. eCollection 2022 Oct. Rheumatol Immunol Res. 2022. PMID: 36788968 Free PMC article. Review.
• CALN1 hypomethylation as a biomarker for high-risk bladder cancer.
  Takagi K, Naruse A, Akita K, Muramatsu-Maekawa Y, Kawase K, Koie T, Horie M, Kikuchi A. Takagi K, et al. BMC Urol. 2022 Nov 9;22(1):176. doi: 10.1186/s12894-022-01136-y. BMC Urol. 2022. PMID: 36352401 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Taylor & Francis

• Other Literature Sources

  • The Lens - Patent Citations